These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
505 related articles for article (PubMed ID: 19491186)
41. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. Correia JB; Patel MM; Nakagomi O; Montenegro FM; Germano EM; Correia NB; Cuevas LE; Parashar UD; Cunliffe NA; Nakagomi T J Infect Dis; 2010 Feb; 201(3):363-9. PubMed ID: 20047501 [TBL] [Abstract][Full Text] [Related]
42. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Perez-Schael I; Salinas B; Tomat M; Linhares AC; Guerrero ML; Ruiz-Palacios GM; Bouckenooghe A; Yarzabal JP J Infect Dis; 2007 Aug; 196(4):537-40. PubMed ID: 17624838 [TBL] [Abstract][Full Text] [Related]
43. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. Bernstein DI; Glass RI; Rodgers G; Davidson BL; Sack DA JAMA; 1995 Apr; 273(15):1191-6. PubMed ID: 7707626 [TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan. Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673 [TBL] [Abstract][Full Text] [Related]
45. Effectiveness of Pentavalent Rotavirus Vaccine in Shanghai, China: A Test-Negative Design Study. Ma W; Wei Z; Guo J; Lu L; Li J; Cai J; Wang X; Chang H; Huang Z; Guo X; Zhu Q; Xu J; Zeng M J Pediatr; 2023 Aug; 259():113461. PubMed ID: 37172809 [TBL] [Abstract][Full Text] [Related]
46. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. Groome MJ; Page N; Cortese MM; Moyes J; Zar HJ; Kapongo CN; Mulligan C; Diedericks R; Cohen C; Fleming JA; Seheri M; Mphahlele J; Walaza S; Kahn K; Chhagan M; Steele AD; Parashar UD; Zell ER; Madhi SA Lancet Infect Dis; 2014 Nov; 14(11):1096-1104. PubMed ID: 25303843 [TBL] [Abstract][Full Text] [Related]
47. Impact and effectiveness of RotaTeq® vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland. Vesikari T; Uhari M; Renko M; Hemming M; Salminen M; Torcel-Pagnon L; Bricout H; Simondon F Pediatr Infect Dis J; 2013 Dec; 32(12):1365-73. PubMed ID: 24051998 [TBL] [Abstract][Full Text] [Related]
48. Effectiveness of pentavalent rotavirus vaccine against severe disease. Staat MA; Payne DC; Donauer S; Weinberg GA; Edwards KM; Szilagyi PG; Griffin MR; Hall CB; Curns AT; Gentsch JR; Salisbury S; Fairbrother G; Parashar UD; Pediatrics; 2011 Aug; 128(2):e267-75. PubMed ID: 21768317 [TBL] [Abstract][Full Text] [Related]
49. Timing of Rotavirus Vaccine Doses and Severe Rotavirus Gastroenteritis Among Vaccinated Infants in Low- and Middle-income Countries. Gruber JF; Becker-Dreps S; Hudgens MG; Brookhart MA; Thomas JC; Jonsson Funk M Epidemiology; 2018 Nov; 29(6):867-875. PubMed ID: 30074540 [TBL] [Abstract][Full Text] [Related]
50. Rotavirus vaccination in Central American children. Ulloa-Gutierrez R; Avila-Aguero ML Expert Rev Vaccines; 2014 Jun; 13(6):687-90. PubMed ID: 24702467 [TBL] [Abstract][Full Text] [Related]
51. Literature review to identify evidence of secondary transmission of pentavalent human-bovine reassortant rotavirus vaccine (RV5) strains to unvaccinated subjects. Li Y; Sun X; Fu Y; You X; Hartwig S Vaccine; 2024 Mar; 42(7):1461-1468. PubMed ID: 38355319 [TBL] [Abstract][Full Text] [Related]
52. Effectiveness of 2 rotavirus vaccines against rotavirus disease in Taiwanese infants. Chang WC; Yen C; Wu FT; Huang YC; Lin JS; Huang FC; Yu HT; Chi CL; Lin HY; Tate JE; Parashar UD; Wu HS; Hsiung CA Pediatr Infect Dis J; 2014 Mar; 33(3):e81-6. PubMed ID: 24569388 [TBL] [Abstract][Full Text] [Related]
53. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis. Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424 [TBL] [Abstract][Full Text] [Related]
54. Live attenuated human rotavirus vaccine, Rotarix. Bernstein DI Semin Pediatr Infect Dis; 2006 Oct; 17(4):188-94. PubMed ID: 17055369 [TBL] [Abstract][Full Text] [Related]
55. Effectiveness of rotavirus vaccines in an Australian population: A case-control study. Fathima P; Snelling TL; Gibbs RA Vaccine; 2019 Sep; 37(41):6048-6053. PubMed ID: 31473003 [TBL] [Abstract][Full Text] [Related]
56. Rotavirus disease burden, Nicaragua 2001-2005: defining the potential impact of a rotavirus vaccination program. Amador JJ; Vasquez J; Orozco M; Pedreira C; Malespin O; De Oliveira LH; Tate J; Parashar U; Patel M Int J Infect Dis; 2010 Jul; 14(7):e592-5. PubMed ID: 20022778 [TBL] [Abstract][Full Text] [Related]
57. Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States. Krishnarajah G; Davis EJ; Fan Y; Standaert BA; Buikema AR Vaccine; 2012 May; 30(24):3717-22. PubMed ID: 22214886 [TBL] [Abstract][Full Text] [Related]
58. Risk of Rotavirus Nosocomial Spread After Inpatient Pentavalent Rotavirus Vaccination. Hofstetter AM; Lacombe K; Klein EJ; Jones C; Strelitz B; Jacobson E; Ranade D; Ward ML; Mijatovic-Rustempasic S; Evans D; Wikswo M; Bowen MD; Parashar UD; Payne DC; Englund JA Pediatrics; 2018 Jan; 141(1):. PubMed ID: 29212881 [TBL] [Abstract][Full Text] [Related]